The conversation discusses using ZIX, a combination of Zinc Sulfate and Vitamin B6, for hair loss. The user is considering liquid forms for better absorption and scalp health.
Topical finasteride in a liposomal formulation reduces systemic absorption compared to ethanol solutions. The user is seeking sources for such products, noting that popular options like morr-f are not liposomal.
A user is discussing their experience with finasteride for diffuse thinning without a receding hairline, noting a massive shedding phase in the fourth month that is now slowing down. Other replies are off-topic and not relevant to the treatment discussion.
The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.
Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.
This post and conversation are about the molecular mechanisms triggered by microneedling, specifically its effects on inflammation, tissue remodeling, epithelial proliferation, differentiation, and collagen synthesis. The discussion highlights the potential benefits of microneedling for hair loss treatment.
The user shared progress pictures after 2 months of using Minoxidil 5%, Forcapil, and dermarolling 1.5mm. They experienced initial shedding but noticed slow hair regrowth.
The conversation discusses using a microneedling device on the face after using it on the scalp, with suggestions to use a depth of 0.2mm for facial treatments. Caution and proper sterilization are advised due to the sensitivity of facial skin.
The conversation is about a user's progress with an oral treatment for hair loss using a stack of finasteride, minoxidil, and biotin over two months, noting stabilization after an initial shed. The user mentions using Hims Chews, which are effective but costly, and another user comments that biotin is ineffective.
The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.
First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.
The conversation discusses hair shedding while using 0.5 mg dutasteride daily for 8.5 months, with users sharing experiences of shedding various hair lengths and thicknesses. It is suggested that shedding can be part of the hair cycle synchronization and may not indicate worsening hair loss.
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
Combining spironolactone with koshine might enhance the effect of blocking androgen receptors for hair loss treatment. The user suggests adding crushed spironolactone pills to koshine.
The conversation discusses hair loss treatments, specifically the effectiveness and legitimacy of low-level laser therapy (LLLT) devices under $200. The user has seen positive results with finasteride, minoxidil, ketoconazole, microneedling, and scalp massages, and seeks advice on affordable LLLT options.
A user is seeking recommendations for purchasing 1mm to 1.5mm derma rollers in the U.S. for better hair growth results, as they are currently using a 0.25mm roller.
Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.
The user switched from oral minoxidil to topical minoxidil and added JXL-069/PP405-3HP, along with topical dutasteride, melatonin, and tretinoin. They also use low-level laser therapy (LLLT) but doubt its effectiveness.
Hair loss concerns and treatments like Minoxidil and Finasteride are humorously discussed. The community's quirks and dedication to battling hair loss are highlighted.
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
Avixis Alfatradiol is a topical 5-alpha reductase inhibitor available in Latin America and Germany, but its effectiveness is questioned. A user reported worsened hair loss after using it and recommended finasteride instead due to its proven effectiveness and lower cost.
The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.
The conversation discusses identifying permanent hair loss and includes treatments like microneedling and biotin vitamins. The user is unsure whether the reduction in wispy hairs is due to hair revitalization or loss.
The user "NotYourMothersDildo" shared their progress pictures after using finasteride and oral minoxidil for 60 days. They noticed significant improvements in hair thickness, texture, and growth, including their mustache and beard.
Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.
Microneedling for hair loss is discussed, with users mentioning using 0.6mm needles twice a week. Treatments like Minoxidil, finasteride, and RU58841 are implied but not directly mentioned.